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H I G H L I G H T S
• MPH modulates BOLD responses to reward-predicting cues in ADHD.• MPH enhanced striatal discrimination of reward and non-reward cues in ADHD.• MPH reduced corticostriatal connectivity during cued reward in ADHD.• Therapeutic effects of MPH may involve altered reward processing.
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A B S T R A C T
Attention deficit hyperactivity disorder (ADHD) has been associated with neural hyposensitivity to reward-
predicting cues. Methylphenidate is widely used in the management of the disorder's symptoms, but its effects on
reward sensitivity in ADHD are unknown. The current study used fMRI to measure striatal responses to reward-
predicting cues in adults with ADHD on and off methylphenidate and a control group, during a classical con-
ditioning task. Responses to cued reward were also explored. Larger differences in the ventral striatum activation
to reward cues versus non-reward cues were observed when the ADHD participants were on methylphenidate
compared to placebo. In response to cued-reward outcome, an exploratory analysis showed methylphenidate
reduced the BOLD time-series correlation between the dorsal striatum and dorsal medial prefrontal cortex.
Methylphenidate's therapeutic effects may be mediated by altering reward processing in individuals with ADHD.
1. Introduction
Attention deficit hyperactivity disorder (ADHD) is characterized by
elevated levels of inattention, overactivity and/or impulsivity that im-
pair daily functioning. Symptoms emerge in childhood, often con-
tinuing into adulthood (American Psychiatric Association, 2013). Al-
tered reward sensitivity is hypothesized to contribute to the disorder's
symptoms (Luman et al., 2010; Tripp and Wickens, 2008). Individuals
with ADHD prefer smaller immediate over larger delayed reward
(Sonuga-Barke et al., 2008), perform less well under partial vs. con-
tinuous reinforcement (Barber et al., 1996) and match their behavior
less efficiently to reinforcement availability (Alsop et al., 2016).
Functional magnetic resonance imaging (fMRI) studies consistently
indicate reduced striatal responses to cues that predict reward in ado-
lescents and adults with ADHD (Baroni and Castellanos, 2015; Plichta
and Scheres, 2014). A small number of studies have reported hy-
persensitivity to reward delivery (Furukawa et al., 2014; Paloyelis
et al., 2012; Ströhle et al., 2008).
Studies of reward circuitry provide clues to the pathophysiology of
altered reward sensitivity in ADHD. In typically developing individuals,
a previously neutral cue becomes a conditioned reinforcer after re-
peated pairing with a reward, which helps maintain behavior when
rewards are delayed or discontinuous (Ferster, 1953; Garrud et al.,
1981). Animal studies show dopamine (DA) cells initially fire in re-
sponse to an unexpected reward. When a cue reliably precedes a re-
ward, dopamine cell firing transfers to the cue. This transfer involves
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two separate processes: an increase in the DA response to the cue, to-
gether with a decrease in the DA response to reward as it becomes more
predictable (Pan et al., 2005; Schultz, 1998). Reduced striatal respon-
siveness to reward-predicting cues, and increased responsiveness to
cued reward are observed in fMRI studies (Baroni and Castellanos,
2015; Furukawa et al., 2014; Paloyelis et al., 2012; Plichta and Scheres,
2014; Ströhle et al., 2008) which suggests these processes may be dis-
rupted in ADHD (Tripp and Wickens, 2008).
Methylphenidate (MPH) is widely prescribed for ADHD (Bolea-
Alamañac et al., 2014; Spencer et al., 1995; Swanson et al., 2011). It
improves attention (Solanto et al., 1997), on-task behavior (Pelham
et al., 1993), inhibitory control (Aron et al., 2003) and cognitive per-
formance (Pietrzak et al., 2006). There is also evidence that MPH re-
duces delay discounting (Shiels et al., 2009) and effort discounting
(Wilkison et al., 1995), reduces risky betting in a gambling task (DeVito
et al., 2008), and improves probabilistic reward learning (Luman et al.,
2015). Changes in DA and norepinephrine (NE) availability with MPH,
particularly in the ventral and dorsal striatum and prefrontal cortex,
have been shown in human imaging studies (Rubia et al., 2014; Volkow
et al., 2009; Zimmer, 2017). In rodents, therapeutic, low dose MPH
increased DA and NE availability in the medial prefrontal cortex
(mPFC) and striatum (Berridge et al., 2006; Koda et al., 2010). In
monkeys, oral, low-dose MPH increased DA in the striatum (Kodama
et al., 2017). Seeman and Madras (2002) and Solanto (1998) proposed
that MPH has differential actions on tonic versus phasic dopamine
signaling. This hypothesis recently gained experimental support (Fuller
et al., 2019). By blocking the dopamine transporter, MPH reduces do-
pamine clearance, which causes increased tonic levels of dopamine
(Butcher et al., 1991; Kuczenski and Segal, 1997). Conversely, the in-
creased tonic dopamine has an inhibitory effect on phasic dopamine
release via the action on the dopamine D2 receptors of dopamine
neurons somadendrite and axon terminals, which decreases the excit-
ability of dopamine cells (Lacey et al., 1987) and decreases release from
dopamine terminals (Davis et al., 1997) At the same time, NE actions in
PFC may increase attention to reward-predicting cues, in turn in-
creasing phasic dopamine responses in the striatum on MPH (Kuczenski
and Segal, 2005, 2001). Investigating the effects of MPH on neural
responses to reward stimuli in individuals with ADHD is therefore an
important next step.
Functional imaging studies have shown effects of MPH on response
inhibition and timing estimation (Rubia et al., 2014). Some studies have
assessed the effects of MPH on rewarded cognitive task performance
and associated blood-oxygen-level dependent (BOLD) responses. Me-
thylphenidate normalized increased activation in the orbitofrontal and
superior temporal regions in children with ADHD, compared to con-
trols, during a rewarded sustained attention task (Rubia et al., 2009). In
another study, MPH normalized increased striatal responses during task
switching when the availability of a higher magnitude of reward was
signaled, but only among adults with ADHD who are carriers of the 9-
repeat allele, a polymorphism in the DAT1 gene (Aarts et al., 2015).
Using a gambling task, Evers et al. (2017) showed that MPH reduced
striatal BOLD responses to gain and loss, while increasing expectancy-
related BOLD signals based on the previous outcome, in support of
differential effects of MPH on phasic vs. tonic dopamine responses.
Imaging studies have shown hyposensitivity to reward-predicting
cues in ADHD, using a variant of the Monetary Incentive Delay task
(Baroni and Castellanos, 2015; Knutson et al., 2001; Knutson and
Heinz, 2015; Plichta and Scheres, 2014) or a classical conditioning task
(Furukawa et al., 2014). Altered reward responses during these tasks
were reported in studies using medication naive (Carmona et al., 2011;
Edel et al., 2013; Furukawa et al., 2014), medicated, or mixed samples
(Hoogman et al., 2011; Plichta et al., 2009; Scheres et al., 2007; Ströhle
et al., 2008), tested off medication. Stimulant treatment history did not
affect the responses (Stoy et al., 2011). However, up to now, no studies
have tested the acute effects of MPH on these tasks.
The findings of the reduced BOLD responses to reward anticipation
in ADHD were mostly in the ventral striatum (Baroni and Castellanos,
2015; Plichta and Scheres, 2014). However, MPH has been shown to
affect other brain regions (Del-Ben et al., 2001; Grevet et al., 2005).
Multiple pathways to ADHD symptoms (Ma et al., 2016; Sonuga-Barke
et al., 2008) and network-based dysfunctions in ADHD (Petrovic and
Castellanos, 2016; Plichta et al., 2013; Sonuga-Barke and Fairchild,
2012) have been proposed. Studies examining task-based functional
connectivity in ADHD suggest reduced attentional network connectivity
but enhanced motivational networks in the presence of reward during
cognitive tasks (Rubia, 2018). Given these studies, and the studies
showing a therapeutic dose of MPH altering the DA and NA availability
in the striatum and mPFC (Berridge et al., 2006; Koda et al., 2010;
Kodama et al., 2017), it is important to examine the effects of MPH on
functional relationships between multiple brain regions in response to
reward cues in ADHD.
In this study, we measured functional activations in the ventral
striatum (VS) in response to reward-predicting cues, in adults with
ADHD on and off MPH and a typically-developing control group. We
also explored BOLD responses to cued-reward outcome, and the degree
to which activation in the striatum is correlated with activation in
mPFC regions. A classical conditioning task involving repeated pre-
sentation of cues and rewards was employed. This task was chosen
because it is not confounded by operant behavioral responses, decision-
making, complex reward probability, timing or magnitude estimation.
The ADHD participants were all known MPH responders. Motivation
and associative-learning were confirmed by participants’ ratings and
behaviors before, during and after the fMRI task. To our knowledge,
this is the first fMRI study to examine the acute effects of MPH on re-
ward-predicting cues.
Based on earlier studies, we hypothesized reduced VS activation in
response to reward-predicting cues (Baroni and Castellanos, 2015;
Plichta and Scheres, 2014) in those with ADHD on placebo, compared
to controls. The role of VS in reward processing has been consistently
indicated across a range of studies (Baroni and Castellanos, 2015;
Knutson and Heinz, 2015; Plichta and Scheres, 2014; Schultz, 1998).
We predicted that MPH would increase VS activation to reward-pre-
dicting cues, in adults with ADHD. We also expected increased VS ac-
tivation in response to cued-reward outcome in the ADHD participants
during placebo, compared to controls (Furukawa et al., 2014; Paloyelis
et al., 2012; Ströhle et al., 2008). We expected a dampening of such
activation in the ADHD participants in the presence of MPH.
Based on suggestions that the effects of MPH involve modulation of
the corticostriatal network (Kodama et al., 2017), we also hypothesized
drug effects on correlations between the striatal and cortical regions.
The correlational analyses were exploratory; the dorsal striatum (DS)
and medial prefrontal cortex (mPFC) regions were examined in addition
to the ventral striatum. The DS receives dopaminergic inputs as strongly
as the VS (Balleine et al., 2007; Everitt and Robbins, 2013; Graybiel and
Grafton, 2015). Effects of low dose MPH on mPFC regions have been
demonstrated in rodents (Berridge et al., 2006; Koda et al., 2010).
Therapeutic effects of MPH on attention (Solanto et al., 1997) and
cognitive performance (Pietrzak et al., 2006) in children with ADHD
implicate the mPFC in the drug's mechanisms of action. Given the ex-
ploratory nature of the analysis, bi-directional effects were tested. We
expected the inter-regional BOLD time-series correlations of ADHD
participants on placebo to differ from those of controls, and that this
difference would be normalized by MPH. Increased correlations would
be expected from previous findings showing a heightened motivational
network in the presence of reward in ADHD (Rubia, 2018). MPH en-
hancing DA and NE availability could either increase or decrease the
corticostriatal inter-regional coupling. Increased tonic DA could reduce
phasic responses to reward-predicting cues and/or cued reward in the
striatum. However, with a low, therapeutic dosage of MPH, increased
prefrontal NE availability might work to enhance attention to cues,
which may also influence striatal DA release in response to cues.
Temporal co-variation, rather than mean BOLD activity levels, might
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thus better capture functional changes induced by MPH.
2. Methods
The study was approved by the ethics committee of the D’Or
Institute for Research and Education (IDOR) in Rio de Janeiro, Brazil.
All volunteer participants provided written informed consent. They
were informed that they would not be paid for their participation but
would be reimbursed for transportation expenses and receive a gift
voucher in the amount earned in the experiment (actual earnings re-
ceived varied between R$ 30 and R$ 50).
2.1. Participants
Participants were right-handed adults aged 22–34 years (Table 1).
ADHD and control participants were recruited from area physicians,
students attending the Federal University of Rio de Janeiro, Brazil, and
through personal contacts.
All participants underwent a comprehensive assessment of past and
current symptoms of ADHD and comorbidity, by a team of qualified
psychiatrists at IDOR, trained and supervised by a senior psychiatrist
(PM). Semi-structured interviews confirmed the presence and severity
of ADHD symptoms or their absence (for controls) (Kiddie-Schedule for
Affective Disorder and Schizophrenia-PL (KSADS-PL) (Grevet et al.,
2005)), and evaluated comorbid conditions (Structured Clinical Inter-
view (SCID) (Del-Ben et al., 2001)). The ADHD participants met DSM-5
criteria for ADHD before 12 years of age and demonstrated at least 5
current symptoms of inattention and/or hyperactivity/impulsivity.
Control participants had fewer than 3 current or previous symptoms of
inattention and hyperactivity/impulsivity. Exclusion criteria were:
current non-prescription drug use, psychotic symptoms, or major de-
pressive or bipolar disorder, and history of any neurological disorder.
All ADHD participants were previously treated with MPH for at least 4
months. Most of the participants did not begin stimulant treatment until
they were adolescents or adults.
The following participants were excluded from data analysis: six
controls (one with childhood ADHD symptoms, two due to movement-
related artifacts, three due to behavioral responses (see below)) and
four ADHD participants (one not meeting the DSM-5 ADHD criteria, one
with a comorbid condition set as an exclusion criteria, one did not re-
turn for the 2nd session, one due to MRI technical problems). The final
sample included 18 participants in the ADHD group and 20 participants
in the control group. The mean ages of the two groups were not sig-
nificantly different (t(36)= 1.66, p= .106). Estimated IQ (Wechsler
Abbreviated Scale of Intelligence Vocabulary and Block Design subtests
(Nascimento, 2004)) was significantly higher for the ADHD than the
control group (t(36)= - 2.43, p= .021). The mean years of education
was higher for the control than the ADHD group (t(36)= 2.41,
p= .021), while the mean income classification score was higher for
the ADHD group (t(36)= - 2.07, p= .046). All participants belonged to
middle and upper socioeconomic classes (Class C1 through A1; the
Brazilian Association of Market Research Companies (http://www.
abep.org/).
Control participants were scanned once, while ADHD participants
were scanned twice, on and off MPH, at least 5 days and on average 15
days apart. Medication and placebo sessions were counterbalanced
across participants. All fMRI sessions were conducted in the morning.
Participants were asked not to eat before arrival. Breakfast (a glass of
chocolate milk, a slice of white bread with a slice of cheese and ham)
was offered, followed by administration of clinical interviews or ques-
tionnaires then the fMRI task.
2.2. MPH dosing
All but two ADHD participants were prescribed extended-release
MPH (Concerta or Ritalin LA), average daily dose 40mg.1 ADHD par-
ticipants were asked to withhold their usual stimulant medication for
48 h prior to each session. Compliance was confirmed on both days.
After breakfast, they were given immediate-release MPH (20mg) or
placebo (capsules). Methylphenidate and placebo administration were
double blind and counterbalanced. However, the final dataset included
12 ADHD participants receiving placebo, and 6 MPH, during the first
session, due to participant dropout and data exclusion. Members of the
research team were blind to medication order until after data collection
and cleaning. Scanning began 1.5 h after MPH or placebo. After com-
pleting the fMRI task, participants rated how much they liked the
medication taken on a 4 point-scale. Mean likability was slightly higher
for MPH (M=2.50, SD=1.04) than placebo (M=1.94, SD=0.80),
this difference was not significant (t(17)= - 1.43, p= .172).
2.3. fMRI experimental paradigm
To examine the effects of reward-predicting cues and cued-reward
Table 1
Participant characteristics.
ADHD Control
(n= 18) (n= 20)
Mean sd Range Mean sd Range
Age (years) 25.61 2.93 22–33 27.35 3.47 22–34
Estimated IQ 110.97 8.05 97.5–127.5 105.42 5.44 92.5–112.5
Education (years) 16.22 1.40 13–19 17.60 2.04 15–21
Socioeconomic classification (IBGE) 36.06 7.56 20–45 31.05 6.97 18–45
Males n (%) 13 (72.2%) 8 (40%)
ADHD Inattention (ASRS Sum) 27.89 4.62 20–35 10.35 4.57 3–18
ADHD Hyperactivity/Impulsivity (ASRS Sum) 20.42 7.72 8–32 10.70 4.17 3–18
Presentation (n: Inattention/Hyperactivity/Combined) 12/0/6
Comorbidity (n: Anxiety/Eating/OCD) 1/3/1 0/0/1
Stimulant Medication (MPH) Median Mode Range
Current (months) 9.5 6 4–117
First medication intake (months prior to study) 20.5 6 5–144
1 The average daily dose was 39.6mg for 10 participants prescribed Concerta,
43.3mg for 3 participants prescribed Ritalin LA, 38mg for 3 participants pre-
scribed a mixture of Ritalin (immediate-release) and Concerta or Ritalin LA, and
45mg for 2 participants prescribed Ritalin.
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outcomes, a classical conditioning task was used in an event-related
design (Fig. 1). A picture of a slot machine was presented with one of
two initially neutral stimuli (two Japanese characters deemed abstract
by Brazilian participants; Cue A or Cue B). Two sets of cues were used
and counterbalanced across the two sessions for ADHD participants.
The slot machine spun for 6 s. The duration between a cue and outcome
was kept constant to maintain the temporal predictability of outcome
delivery (Furukawa et al., 2014; Metereau and Dreher, 2013). At-
tenuation of neural responses to reward outcome is observed only when
reward can be predicted (Hollerman and Schultz, 1998)2. After the
delay, the slot machine stopped at a win or non-win position (reward or
non-reward) for 2 s. After each outcome, participants were asked to
‘suggest’ to the computer which machine to play next (same machine
and cue or switch) by a button press (the actual presentation was
pseudo-random). The response options were available for 1 s, followed
by a variable inter-trial delay to reduce the temporal predictability of
the next trial (Poisson distribution: min=4 s, median=6 s). The
button press was included to maintain engagement during the classical-
conditioning task and to allow checking of ongoing attention and pre-
ferences between the two slot machines.
Participants completed a brief training run on a computer before
entering the MRI scanner, exposing them to the cue and outcome sti-
muli and familiarizing them with the button press response. Training
consisted of 4 trials of Cue A (CS+) followed by a reward, 2 trials of
Cue A followed by non-reward, and 4 trials of Cue B (CS-) followed by
non-reward, in a pseudo-random order. Participants were asked to
indicate which symbol (cue) they preferred. Within the MRI scanner,
Cue A was followed by reward 66% of the time (44 trials) and non-
reward 33% of the time (22 trials). Cue B was always followed by non-
reward (44 trials). Participants were told that they could earn up to R$
50 during the experiment.
2.4. Ratings and behavioral measures before, during and after the fMRI task
Several self-report and behavioral measures were used to assess
motivation, attention to the task, classical-conditioning effects and
awareness of the cue-outcome association. At the beginning of the ex-
periment, participants were asked to rate their motivation to earn
money in the experiment. Motivation ratings were not significantly
different for the ADHD placebo (M=2.83, SD=0.71), ADHD MPH
(M=2.89, SD=0.68), and control (M=2.85, SD=0.75) participants
(F(2, 55)= 0.03, p= .971).
During the fMRI task, the participants' button-press responses were
recorded. Participants sometimes missed the response window (1 s).
The percentage of missed responses ranged from 0 to 22%, except for
one control participant (60%). Participants’ suggestions to stay with the
same machine after Cue A trials (regardless of the outcome) or to switch
machines after Cue B trials indicated a preference for CS+. All but one
control participant showed a consistent preference for the reward-pre-
dicting cue.
Participants’ explicit awareness of the cue types was checked by
asking them to indicate which of the two symbols (cues) they preferred
after the training session and after completing the classical conditioning
task in the scanner. All but four control participants indicated they
preferred CS+ over CS- after training, three of them indicating a pre-
ference for CS+ after completing the fMRI task. One ADHD participant
did not indicate such a preference after training or completing the first
session (placebo), but did show a preference for CS+ in the second
Fig. 1. Classical conditioning fMRI task. One of the two neutral stimuli (Cue A or Cue B) was followed by an outcome stimulus (reward or non-reward) after a 6-
second delay. Cue A was followed by the delivery of the reward 66% of the time and non-reward 33% of the time. Cue B was always followed by non-reward.
2 It has been shown that when rewards are delivered a half second before the
expected timing of the reward, dopamine neurons fire at the time of the reward
delivery. When rewards are delayed, dopamine neurons show an undershoot of
activity at the time of the expected, undelivered reward, and fire when the
reward is eventually delivered later (Hollerman and Schultz, 1998).
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session (MPH). Two control participants, one who missed the button-
press responses 60% of the time, and another who did not show a be-
havioral preference for the CS+ in the scanner and did not indicate an
explicit preference for the CS+ after training, were excluded from data
analysis.
Conditioning effects were also evaluated using a Pavlovian-to-in-
strumental transfer (PIT) procedure (da Costa et al., 2019)
(Supplemental Fig. 1). Before the fMRI classical conditioning task,
participants completed an independent operant procedure, which re-
quired them to apply force to a hand dynamometer repeatedly to obtain
monetary rewards. After the fMRI task, participants were asked to
complete the same operant procedure again, but this time with Cue A
and Cue B present, and outcomes hidden (transfer phase). Invigoration
of behavioral responses during the transfer phase demonstrated that
classical conditioning of Cue A to reward was effective for ADHD par-
ticipants on and off MPH and control participants. Frequency of re-
sponses and grip force applied in the presence of the reward cue were
greater than the non-reward cue for the ADHD placebo (frequency t
(17)= 11.47, p < .001; force t(17)= 5.69, p < .001), ADHD MPH
(frequency t(17)= 10.45, p < .001; force t(17)= 7.82, p < .001),
and control (frequency t(19)= 7.12, p < .001; force t(19)= 5.29,
p < .001) participants.
2.5. fMRI image acquisition
Functional images were acquired with a 3T Philips Achieva scanner,
using an 8-channel SENSE head coil, LCD display with a mirror, shingle-
shot T2*-weighted fast-field echo, echo-planar imaging sequence
(TR = 2000 ms, TE = 22 ms, Matrix = 80 x 80, FOV = 240 mm, flip
angle = 90, isotropic voxel size 3 mm, 37 slices in ascending order with
no gap), a SENSE factor of 2, dynamic stabilization, and paddings and
straps over the forehead and under the chin. Reference anatomical
images were acquired using a T1-weighted SD magnetization-prepared,
rapidly acquired gradient echo sequence (TR/TE = 7.2/3.4 s, Matrix/
FOV = 240/240 mm, flip angle = 8°, 1 mm isotropic voxel size, 170
sagittal slices). Each scanning session comprised 3 runs, 285 vol each,
total functional scanning time 28.5 min. The trial number, sequence
and time were uniform across all the participants, and two sessions for
the ADHD group.
2.6. fMRI analysis
2.6.1. Preprocessing
The functional images were analyzed using Statistical Parametric
Mapping software (SPM12; http://www.fil.ion.ucl.ac.uk/spm/
software/spm12/). Preprocessing used realignment, slice-time correc-
tion (referencing slice 19), co-registration, and normalization to the
standard echo planar imaging template (MNI: Montreal Neurological
Institute) resulting in the reconstructed functional images with voxel
dimensions of 3mm. Images were spatially smoothed (6mm Gaussian
kernel). Boxcar functions at stimulus onset for specified events were
convolved with the hemodynamic response function with autocorrela-
tion correction (AR(1)) and high-pass filtering (128 s) for each parti-
cipant.
Seven condition-specific regressors (Cue A, Cue B, Cue A reward,
Cue A non-reward, Cue B non-reward, button press and ITI Fixation)
were entered together with six movement parameters. The variance
inflation factors (VIF) of all regressors of interest (Cue A, Cue B, Cue A
reward, Cue A non-reward, Cue B non-reward) were under 1.5 (https://
github.com/canlab/CanlabCore/blob/master/CanlabCore/diagnostics/
scn_spm_design_check.m), indicating a low level of collinearity in the
task design (Mumford et al., 2015). Based on the SPM collinearity test,
the cue and outcome conditions were orthogonal (ranged from 0.00 to
0.05 for all participants). The Finite Impulse Response (FIR) model was
applied with event duration of 0s. The effect of CS+ (Cue A vs. Cue B)
was the main contrast of interest. Secondarily, the effect of cued-reward
outcome (Cue A reward vs. Cue B non-reward) was explored. While the
outcome was probabilistic and the regressors of interest showed ac-
ceptable levels of collinearity, it is well known that the hemodynamic
nature of BOLD effects is sluggish, taking around 6 s to return to
baseline. For this reason, observed BOLD responses associated with the
reward delivery may reflect a compound effect of cue and outcome.
2.6.2. Region-of-interest (ROI) analyses
Mean parameter estimates from the 5mm sphere around the bi-
lateral ventral striatum MNI coordinates were extracted for each con-
dition of interest (Cue A, Cue B, Cue A reward, Cue B non-reward) using
the rfxplot toolbox (http://rfxplot.sourceforge.net/). The coordinates
(12/-12, 10, −6 for rVS/lVS [nucleus accumbens]) were the same
meta-analytical coordinates (Liu et al., 2011) used in our previous study
(Furukawa et al., 2014) examining striatal responses to reward-pre-
dicting cue and cued-reward outcome in ADHD. Extracted mean para-
meter estimates were analyzed in SPSS 23 (https://www.ibm.com/
analytics/spss-statistics-software). Two-way repeated-measures AN-
OVAs, using SPSS GLM, examined the within-subject effects of condi-
tion (Cue A vs. Cue B; Cue A reward vs. Cue B non-reward) and med-
ication status (MPH vs. placebo) on BOLD responses (parameter
estimates extracted for each condition), controlling for medication
order (0, 1), in participants with ADHD. Separately, two-way mixed
ANOVAs, using SPSS GLM, examined the within-subject effects of
condition (Cue A vs. Cue B; Cue A reward vs. Cue B non-reward) and
the between-subject effects of group (control vs. ADHD placebo; control
vs. ADHD MPH) on BOLD responses. Bonferroni family-wise error
(FWE) corrections were applied for the two striatal regions and FWE
corrected p values (i.e., p multiplied by two) are presented.
2.6.3. Exploratory correlational analyses
To examine the degree to which BOLD responses in the striatum was
correlated with responses in the mPFC, the images were further pro-
cessed and evaluated in CONN17, www.conn-toolbox.org/(Whitfield-
Gabrieli and Nieto-Castanon, 2012). White matter and cerebrospinal
fluid BOLD-time series were modeled as voxel-specific noise effects,
together with movement covariates (Whitfield-Gabrieli and Nieto-
Castanon, 2012). In addition to the ventral striatum (rVS/lVS), dorsal
striatum (rDS/lDS) and three mPFC regions (medial prefrontal/orbito-
frontal cortex [mPFC/OFC], dorsal portion of the medial prefrontal
cortex [dmPFC], and anterior cingulate cortex [ACC]) were included in
the exploratory correlational analyses. The bilateral ventral striatum
were defined in CONN using the same coordinates and 5mm sphere as
the ROI analyses. The 5mm spheres were drawn for the other regions
using the following coordinates based on previous literature: 20/-20, 4,
18 for rDS/lDS (Liu et al., 2011); 0, 54, −8 for mPFC/OFC (Moll et al.,
2012), 0, 62, 19 for dmPFC (Moll et al., 2012); −2, 40, −4 for aCC
(Clithero and Rangel, 2014). The average BOLD time series was cal-
culated across voxels within each region, and a correlation coefficient
was computed for each pair of regions. The same conditions of interest
and no-interest as the ROI analyses were applied. An initial examina-
tion of bivariate correlation coefficients showed moderate to high
correlations for some participants. Thus, semi-partial correlation coef-
ficients were estimated to examine uniquely shared variance by each
striatal seed region with each cortical region.
GLM examined within-subject medication effects (MPH vs. placebo)
and between-subject group effects (control vs. ADHD placebo, control
vs. ADHD MPH) on the Fisher r-to-z transformed semi-partial correla-
tion coefficients of the reward cue contrast (Cue A vs. Cue B) and cued
reward contrast (Cue A reward vs. Cue B non-reward). For each striatal
seed, an omnibus F-test evaluated multivariate effects across six target
regions (i.e., a seed-level difference according to medication status or
group membership for the cue or reward contrast). The models for
further inspection were selected based on this seed-level threshold
(p < .05, uncorrected). For the selected models, paired or independent
t-tests, respectively, examined the differences in the strength of
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correlations between a seed and each target region, two-tailed, FWE
corrected for the six pairs per seed. Bonferroni FWE corrected p values
(i.e., p multiplied by six) are presented.
2.6.4. Further examination of relationship between BOLD responses in two
regions
To understand the nature of a significant difference in correlation
strengths, post-hoc analyses were conducted in SPSS with correlation
coefficients extracted from CONN. In addition, to visualize the re-
lationship between BOLD responses in the two regions, eigenvariate
values for the same region spheres were extracted from SPM for the
control and ADHD group participants (during the placebo and MPH for
the ADHD group) and were displayed in a scatter plot.
3. Results
3.1. Region-of-interest analyses
3.1.1. Medication effects on the ventral striatum responses to reward-
predicting cue
Medication (MPH vs. Placebo) and condition (Cue A vs. Cue B)
within-subject effects were examined for the bilateral striatal regions.
For the rVS responses, a significant medication*condition interaction
effect (F(1, 16) = 6.87, p= .038, FWE), together with a main effect of
condition (F(1, 16)= 6.48, p= .044, FWE), were observed. There was
no significant main effect of medication (F(1, 16)= 0.44, p = 1.03,
FWE). For the lVS responses, a significant medication*condition inter-
action effect was also observed (F(1, 16) = 6.60, p= .042, FWE), while
there was no significant main effect of medication (F(1, 16)= 1.02,
p= .656, FWE) or condition (F(1, 16)= 3.78, p= .140, FWE). Greater
differences in BOLD responses to Cue A vs. Cue B were observed when
the ADHD group participants were on MPH, compared to placebo, for
the bilateral ventral striatum.
3.1.2. Group differences in the ventral striatum responses to reward-
predicting cue
Group (control vs. ADHD Placebo) between-subject and condition
(Cue A vs. Cue B) within-subject effects were examined. A main effect of
condition was observed in the rVS (F(1, 36)= 7.57, p= .018, FWE).
There was no significant effect of group (F(1, 36)= 0.70, p = .816,
FWE) or group*condition interaction (F(1, 36) = 0.02, p=1.79, FWE).
For the responses in the lVS, no significant effect was observed for
condition (F(1, 36)= 3.87, p= .011, FWE), group (F(1, 36)= 0.38,
p = 1.09, FWE), or group*condition interaction (F(1, 36) = 0.08,
p=1.56, FWE).
Group (control vs. ADHD MPH) between-subject and condition (Cue
A vs. Cue B) within-subject effects were also examined. Main effects of
condition were observed in the rVS (F(1, 36)= 15.43, p < .001, FWE)
and lVS (F(1, 36)= 8.07, p= .014, FWE). No significant effect of group
was observed for the rVS (F(1, 36)= 1.61, p= .426, FWE) or lVS (F(1,
36)= 0.29, p = 1.19, FWE). There was no group*condition interaction
effect for the rVS (F(1, 36) = 1.10, p= .600, FWE) or lVS (F(1,
36)= 1.42, p= .484, FWE).
BOLD responses to the reward predicting cue were greater than
responses to the non-reward predicting cue across groups in the bi-
lateral striatum (Fig. 2a).
3.1.3. Medication effects on the ventral striatum responses to cued-reward
outcome
Medication (MPH vs. Placebo) and condition (Cue A reward vs. Cue
B non-reward) within-subject effects were explored for the bilateral
striatal regions. A condition main effect was observed in the rVS (F(1,
16)= 6.68, p= .040, FWE). There was no significant effect of medi-
cation (F(1, 16)= 2.60, p = .254, FWE) or medication*condition in-
teraction (F(1, 16) = 1.07, p= .632, FWE). During MPH and placebo,
increased BOLD responses were observed to cued reward, compared to
cued non-reward, in the right ventral striatum. No significant effect of
medication (F(1, 16)= 5.46, p= .066, FWE), condition (F(1,
16)= 4.98, p = .080, FWE), or medication*condition interaction (F(1,
16) = 1.34, p= .528, FWE) was observed for the lVS responses.
3.1.4. Group differences in the ventral striatum responses to cued-reward
outcome
Group (control vs. ADHD Placebo) between-subject and condition
(Cue A reward vs. Cue B non-reward) within-subject effects were ex-
amined. Main effects of condition were observed in the rVS (F(1,
36)= 8.17, p= .014, FWE) and lVS (F(1, 36)= 13.41, p= .002, FWE).
There was no main effect of group for the rVS (F(1, 36)= 0.03,
p=1.74, FWE) or lVS (F(1, 36)= 0.60, p = .892, FWE). No significant
group*condition interaction effect was observed for the rVS (F(1,
36) = 0.00, p=1.98, FWE) or lVS (F(1, 36)= 0.00, p=1.94, FWE).
Group (control vs. ADHD MPH) between-subject and condition (Cue
A reward vs. Cue B non-reward) within-subject effects were also ex-
amined. Main effects of condition were observed in the rVS (F(1,
36)= 9.34, p= .008, FWE) and lVS (F(1, 36)= 9.53, p= .008, FWE).
There was no main effect of group for the rVS (F(1, 36)= 1.37,
p= .498, FWE) or lVS (F(1, 36)= 0.17, p = 1.37, FWE). No significant
group*condition interaction effect was observed for the rVS (F(1,
36) = 0.18, p=1.34, FWE) or lVS (F(1, 36)= 1.78, p= .380, FWE).
BOLD responses to cued reward were greater than responses to cued
non-reward across groups (Fig. 2b).
3.2. Exploratory correlational analyses
In response to reward-predicting cues (Cue A vs. Cue B), omnibus F-
tests were not significant for the bilateral ventral and dorsal striatum
seeds for the effects of medication (placebo vs. MPH) or group (control
vs. ADHD placebo; control vs. ADHD MPH).
In response to cued-reward outcome (Cue A reward vs. Cue B non-
reward), omnibus F-tests were significant for the rVS (F(4, 14)= 6.31,
p= .004) and rDS (F(4, 14)= 3.78, p= .028) seeds for the medication
effects (placebo vs. MPH). Paired t-tests indicated a significant differ-
ence between the correlation of the rVS and mPFC/OFC BOLD time
series during MPH compared to placebo (t(17)= 3.40 p= .020, FWE).
The correlation strength was increased during MPH. Paired t-tests also
indicated a significant difference between the correlation between the
rDS and dmPFC BOLD time series during MPH compared to placebo (t
(17)= - 4.27 p= .003, FWE). The correlation strength was lower
during MPH.
For the ADHD placebo vs. control group comparison, an omnibus F-
test showed a trend effect for the rDS seed (F(6, 31)= 2.37, p= .053).
Independent t-tests indicated that the correlation between the rDS and
dmPFC BOLD time series was larger for the ADHD placebo than for the
control group (t(36)= 3.13 p= .016, FWE). None of the F-tests ap-
proached significance for the ADHD MPH vs. control group comparison.
Semi-partial correlation coefficients for each group are presented,
and significant and non-significant comparisons are noted, in
Supplemental Table 2.
3.3. Post-hoc examination of rVS-mPFC/OFC and rDS-dmPFC correlations
Due to the differential correlations between rVS and mPFC/OFC,
and rDS and dmPFC regions observed during cued-reward outcome,
post-hoc analyses were conducted in SPSS, using the Fisher-transformed
r-to-z values computed in CONN. Two-way mixed ANOVAs, using SPSS
GLM, examined the effects of the condition (Cue A reward and Cue B
non-reward) and group (ADHD placebo, ADHD MPH, and control).
No significant effect of condition (F(1, 53)= 2.12, p= .151), group
(F(2, 53)= 0.06, p = .938) or a group*condition interaction (F(2,
53) = 0.08, p= .926) was observed on the correlation strength be-
tween rVS and mPFC/OFC.
No significant main effect of condition (F(1, 53)= 2.69, p= .107)
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or group (F(2, 53)= 0.88, p = .420) was observed on the correlation
strength between rDS and dmPFC either. However, there was a sig-
nificant group*condition interaction effect (F(2, 53) = 5.23, p= .008,
Fig. 3a). During cued reward (Cue A reward), the ADHD placebo
group's rDS-dmPFC correlation was different from the other two groups
(F (2, 53)= 4.04, p= .023) in a one-way ANOVA, and significantly
greater than zero (t(17)= 3.12, p= .006) in a one-sample t-test.
3.4. Visualization of rDS-dmPFC correlations for the control and ADHD
participants
To visualize and understand the nature of the rDS-dmPFC correla-
tion during cued reward, eigenvariate values from the same 5mm rDS
and dmPFC spheres (Cue A reward vs. Cue B non-reward contrast) were
extracted in SPM and plotted for the control and ADHD participants
(during the placebo and MPH for the ADHD group) (Fig. 3b). The data
are consistent with the results of the CONN analysis.
4. Discussion
The current study showed methylphenidate modulates striatal re-
sponses to reward-predicting cues in young adults with ADHD using a
classical conditioning paradigm. Larger differences in BOLD responses
to reward cues versus non-reward cues were observed when ADHD
participants were on MPH, compared to placebo. The cue contrast
showed significant effects in bilateral ventral striatum for ADHD par-
ticipants on MPH. MPH did not necessarily increase the magnitude of
their striatal responses to reward-predicting cues. Rather, MPH ap-
peared to improve discriminability between the reward and non-reward
cues, i.e., elevated striatal activity was seen only to the reward cues, but
not to the non-reward cues. During placebo, the magnitude of striatal
responses to reward cues and non-reward cues were similar.
Methylphenidate is the first line pharmacological treatment for
ADHD, and its positive effects on behavioral symptoms and cognitive
performance are well documented (Bolea-Alamañac et al., 2014;
Spencer et al., 1995; Swanson et al., 2011). Methylphenidate increases
postsynaptic DA and NE availability (Rubia et al., 2014; Volkow et al.,
2009; Zimmer, 2017), which are strongly implicated in the brain's re-
ward mechanisms. Previous behavioral and imaging research has con-
sistently indicated altered reward processing in ADHD, leading to
suggestions that MPH might act by modulating responses to reward
stimuli. The current study provides the first direct evidence that MPH
has acute effects on hemodynamic responses to reward-predicting cues
in the ventral striatum. Questions remain, however, regarding whether
such effects are unique to individuals with ADHD. No significant group
difference was observed between the controls and ADHD participants
during placebo in the mean activation levels in the ventral striatum.
Control participants were not scanned on MPH.
Exploratory analyses were carried out to examine how striatal re-
sponses may relate to BOLD responses in mPFC. The finding of sig-
nificant MPH effects on the correlation of ventral striatum and medial
prefrontal/orbitofrontal cortex, and of dorsal striatum and dorsal
medial prefrontal cortex, during cued-reward outcome is consistent
with network-based dysfunction in ADHD (Petrovic and Castellanos,
2016; Plichta et al., 2013; Sonuga-Barke and Fairchild, 2012). For those
with ADHD, the responses to cued reward in rDS and dmPFC shared a
larger variance than the control group, suggesting greater synchrony of
the two regions during placebo. A significant decrease in the strength of
the correlation was observed in the presence of MPH. These results are
consistent with hypersensitivity to reward in ADHD and suggest that
this is mediated by the PFC-striatum network. MPH may reduce hy-
persensitivity by decoupling the rDS and dmPFC. The correlation be-
tween rVS and mPFC/OFC was greater on MPH, compared to placebo.
However, there was no ADHD placebo vs. control group difference.
Variability in the effect of MPH on corticostriatal connectivity may
reflect known anatomical and functional differences in DA innervation
Fig. 3. (A) Means and standard errors of Fisher r-to-z converted rDS-dmPFC correlations during cued-reward and non-reward outcome, and (B) correlations between
rDS and dmPFC 5 mm sphere eigenvariate values during cued reward (Cue A reward vs. Cue B non-reward).
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in these regions (Saunders et al., 2018).
The ventral striatum regions were evaluated a-priori; the reduced
responsiveness to reward-predicting cues in individuals with ADHD
have been consistently documented (Baroni and Castellanos, 2015;
Plichta and Scheres, 2014). The examination of BOLD correlations in
the dorsal striatum and medial prefrontal cortex were exploratory; the
results are consistent with the existing literature. The dorsal striatum
exhibits neural activity in relation to the learned association of sensory
cues with movements, and receives strong dopaminergic inputs
(Balleine et al., 2007; Everitt and Robbins, 2013; Graybiel and Grafton,
2015). Dopamine action on the dorsal striatal neurons during pre-
paration for the button-press required after an outcome might underlie
the observed hemodynamic effects (Wickens et al., 2003). Dorsal
striatum is also thought to play a greater role in the later stages of
associative learning (Everitt and Robbins, 2013). The medial prefrontal
cortex receives a wide range of limbic and sensory inputs, while pro-
jecting to the striatum and motor cortex (Euston et al., 2012; Ishikawa
et al., 2008). The dorsal mPFC is thought to provide a context (e.g.,
reward availability) for action (Euston et al., 2012).
In terms of mechanisms of action, we speculate that at therapeutic
doses, MPH's effects on striatal dopamine signals in ADHD may be ex-
erted through increased norepinephrine availability in the medial pre-
frontal cortex (Kuczenski and Segal, 2005, 2001). Effects of nor-
epinephrine include improved attention, which could secondarily affect
dopamine release in response to conditioned cues in the striatum. Me-
thylphenidate has also been shown to increase tonic levels of dopamine,
while reducing phasic dopamine release (Fuller et al., 2019; Seeman
and Madras, 2002; Solanto, 1998). This may be reflected in decreased
sensitivity to cued-reward outcomes. The results of the current study
provide some support for these possible mechanisms of action.
In the current experiment, care was taken to ensure that group
differences were not due to differences in the participants' ability to
‘learn’ the cue-reward association. All participants completed a brief
training session before image acquisition in the scanner. The partici-
pants learned the association quickly. Both control and ADHD partici-
pants showed similar preference for the reward-predicting cue over the
non-reward-predicting cue.
Study participants were carefully selected, increasing our con-
fidence that observed effects are due to group membership and drug
condition. Lifetime symptoms of ADHD and functional impairments
were verified by structured clinical interview. No participants demon-
strated cognitive impairment or reported a history of substance use
disorder. Comorbidity rates in the ADHD group were low. All ADHD
participants were stimulant-responders. None were prescribed medi-
cation in childhood or had more than three years exposure to stimulant
treatment with one exception.3
Our study has some important caveats and limitations that need
mention. All ADHD participants reported significant childhood symp-
toms of ADHD but did not begin pharmacotherapy until young adult-
hood. All were willing to suspend medication use during the working
week, suggesting a high functioning subpopulation of ADHD. Given the
on and off medication design, individuals with ADHD were scanned
twice, whereas controls participated only once. Control participants
were not tested on medication, and the control group data was used
twice for the group comparison analyses. Due to randomization and
exclusions, only six participants with ADHD were scanned on MPH in
the first session. For these participants, prior exposure to the paradigm,
albeit with a different set of cues, may have enhanced the conditioning
effect off medication in the second session, reducing any on-off medi-
cation differences. Other possible order effects cannot be excluded. A
placebo effect may have operated for the ADHD participants (Zubieta
and Stohler, 2009). However, likeability ratings for MPH and placebo
were not significantly different. The effects of MPH may not have been
optimized, as doses were not individually titrated against participants’
prescription or body weight (Huss et al., 2017). On the physiological
side, BOLD responses are indirect measures of neural responses and
possess limited temporal resolution. The temporal predictability re-
quired for examining responses to a classically-conditioned cue and to
predicted reward may not have been optimal in separating these two
phases. However, the model estimate showed an adequate level of non-
collinearity among the conditions of interest, likely resulting from the
probabilistic reward design. Finally, functional heterogeneity of striatal
neurons poses challenges when examining spatially-smoothed voxel or
region level data in fMRI. Thus, our study design and sample char-
acteristics may have reduced observed group differences.
5. Conclusions
The current study demonstrated that MPH influences sensitivity to
reward-predicting cues in adults with ADHD. Acute dosing with MPH
appeared to “rescue” the striatal responses to reward cues, enhancing
discrimination between reward cues and non-reward cues.
Methylphenidate was accompanied by changes in cortico-striatal com-
munication in response to cued reward. The effects of MPH on sensi-
tivity to reward-predicting cues and cued-reward outcomes raise the
intriguing possibility that it facilitates an excitatory process for in-
creasing dopamine responses to cues, and an inhibitory process in the
circuitry for reducing responses to predicted reward. These may be due
to the interplay of tonic DA and NE levels in the striatum and prefrontal
cortex, and phasic DA responses in the striatum. Complementary effects
of actions of multiple neurotransmitters in different brain regions are
likely involved. Present knowledge of the neural mechanisms is in-
sufficient to draw conclusions and further research is needed to address
these questions.
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